1361005-73-3Relevant academic research and scientific papers
Palladium-catalyzed cross-coupling of benzyltitanium(IV) reagents with aryl fluorides
Li, Yan
, (2022/01/11)
The first palladium-catalyzed cross-coupling between benzyltitanium(IV) reagents with aryl fluorides is reported. A variety of diarylmethanes can be prepared in good to excellent yields by the catalyst system of PdCl2(dppf)2 associated with 1-[2-(di-tert-butylphosphanyl)phenyl]-4-methoxypiperidine. This reaction offered a highly efficient approach to diarylmethanes that are commonly found in life-changing drug molecules. Graphical abstract: [Figure not available: see fulltext.]
Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors
Yang, Yiqing,Cao, Lin,Gao, Hongying,Wu, Yue,Wang, Yaxin,Fang, Fang,Lan, Tianlong,Lou, Zhiyong,Rao, Yu
supporting information, p. 4056 - 4073 (2019/05/06)
Viral infections are increasing and probably long-lasting global risks. In this study, a chemical library was exploited by phenotypic screening to discover new antiviral inhibitors. After optimizations from hit to lead, a novel potent small molecule (RYL-634) was identified, showing excellent broad-spectrum inhibition activity against various pathogenic viruses, including hepatitis C virus, dengue virus, Zika virus, chikungunya virus, enterovirus 71, human immunodeficiency virus, respiratory syncytial virus, and others. The mechanism of action and potential targets of RYL-634 were further explored by the combination of activity-based protein profiling and other techniques. Finally, human dihydroorotate dehydrogenase was validated as the major target of RYL-634. We did not observe any mutant resistance under our pressure selections with RYL-634, and it had a strong synergistic effect with some Food and Drug Administration-approved drugs. Hence, there is great potential for developing new broad-spectrum antivirals based on RYL-634.
ANTIMALARIAL COMPOUNDS
-
Page/Page column 62; 64, (2012/06/15)
The present invention relates to antimalarial compounds. More specifically, the present invention relates to novel substituted quinolone derivatives of formula (I) and related quinoline derivatives of formula (II) as defined herein that possess potent ant
Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:Quinone oxidoreductase (PfNDH2)
Pidathala, Chandrakala,Amewu, Richard,Pacorel, Bénédicte,Nixon, Gemma L.,Gibbons, Peter,Hong, W. David,Leung, Suet C.,Berry, Neil G.,Sharma, Raman,Stocks, Paul A.,Srivastava, Abhishek,Shone, Alison E.,Charoensutthivarakul, Sitthivut,Taylor, Lee,Berger, Olivier,Mbekeani, Alison,Hill, Alasdair,Fisher, Nicholas E.,Warman, Ashley J.,Biagini, Giancarlo A.,Ward, Stephen A.,O'Neill, Paul M.
, p. 1831 - 1843 (2012/05/04)
A program was undertaken to identify hit compounds against NADH:ubiquinone oxidoreductase (PfNDH2), a dehydrogenase of the mitochondrial electron transport chain of the malaria parasite Plasmodium falciparum. PfNDH2 has only one known inhibitor, hydroxy-2-dodecyl-4-(1H)-quinolone (HDQ), and this was used along with a range of chemoinformatics methods in the rational selection of 17 000 compounds for high-throughput screening. Twelve distinct chemotypes were identified and briefly examined leading to the selection of the quinolone core as the key target for structure-activity relationship (SAR) development. Extensive structural exploration led to the selection of 2-bisaryl 3-methyl quinolones as a series for further biological evaluation. The lead compound within this series 7-chloro-3-methyl-2-(4-(4-(trifluoromethoxy)benzyl)phenyl) quinolin-4(1H)-one (CK-2-68) has antimalarial activity against the 3D7 strain of P. falciparum of 36 nM, is selective for PfNDH2 over other respiratory enzymes (inhibitory IC50 against PfNDH2 of 16 nM), and demonstrates low cytotoxicity and high metabolic stability in the presence of human liver microsomes. This lead compound and its phosphate pro-drug have potent in vivo antimalarial activity after oral administration, consistent with the target product profile of a drug for the treatment of uncomplicated malaria. Other quinolones presented (e.g., 6d, 6f, 14e) have the capacity to inhibit both PfNDH2 and P. falciparum cytochrome bc1, and studies to determine the potential advantage of this dual-targeting effect are in progress.
